Safety-Related Labeling Changes

Ileus , angioedema, cholecystitism Elevations of liver enzymes, hyperbilirubinemia, cholestasis, hepatitis, Medullary thyroid carcinoma , Dysgeusia, dizziness , Increased serum creatinine, acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis.

Trade Name

Xultophy

Updated Section

4.8 Undesirable effects

Month

Oct,2023